Drugs / MK-8616
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03519867 | Aug 2004 → May 2005 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8616 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03519867 ↗ |
| Route | Intravenous | “both Zemuron® and MK-8616 are administered by intravenous (iv) infusion.” NCT03519867 ↗ |